Neovacs
Biotech firm developing immunotherapies and investing in BioTech and MedTech.
ALNEV | Euronext Growth
Overview
Corporate Details
- ISIN(s):
- FR0004032746 (+4 more)
- LEI:
- 9695001J9GMM5XYK6482
- Country:
- France
- Address:
- 14 RUE DE LA REPUBLIQUE, 92150 SURESNES
- Website:
- https://www.neovacs.com/en/
Description
Neovacs is a biotechnology company with two main activities: research and development, and investment. The company's R&D focuses on its proprietary Kinoid technology platform, an active immunotherapy approach for treating autoimmune diseases and allergies. This technology develops therapeutic vaccines designed to stimulate the patient's immune system to regulate the overproduction of harmful cytokines. Key indications for its Kinoid products include lupus. In addition to its internal development, Neovacs invests in high-potential BioTech and MedTech companies, leveraging its experienced team to evaluate and support innovative products and medical devices.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-05-02 18:00 |
Levée de fonds de 0,2 MEUR
|
French | 229.0 KB | ||
| 2024-04-30 23:00 |
Résultats annuels 2023
|
French | 264.1 KB | ||
| 2024-04-10 18:00 |
Information relative au nombre total de droits de vote et d'actions composant l…
|
French | 240.0 KB | ||
| 2024-04-04 08:00 |
Néovacs confirme sa qualification d'Entreprise innovante
|
French | 213.3 KB | ||
| 2024-04-02 20:00 |
Ajustement de la valeur nominale
|
French | 209.4 KB | ||
| 2024-03-21 08:00 |
Avancées des programmes de candidats vaccins thérapeutiques en collaboration av…
|
French | 233.9 KB | ||
| 2024-02-26 08:00 |
Néovacs dans le Top5 des avancées scientifiques selon l'Inserm
|
French | 240.0 KB | ||
| 2024-02-14 18:00 |
Information relative au nombre total de droits de vote et d'actions composant l…
|
French | 233.0 KB | ||
| 2024-02-14 08:00 |
Néovacs annonce l'entrée en phases nationales du brevet sur ses vaccins à ARNm …
|
French | 227.9 KB | ||
| 2024-01-10 08:00 |
Néovacs et l'hôpital Foch s'engagent sur un nouveau partenariat axé sur la rech…
|
French | 214.4 KB | ||
| 2024-01-02 18:00 |
Information relative au nombre total de droits de vote et d'actions composant l…
|
French | 241.9 KB | ||
| 2023-12-20 08:00 |
Regroupement des actions Néovacs et suspension des conversions
|
French | 233.0 KB | ||
| 2023-12-19 19:00 |
Information relative au nombre total de droits de vote et d'actions composant l…
|
French | 240.8 KB | ||
| 2023-12-18 08:00 |
Néovacs annonce la validation de ses vaccins à ARNm dans les allergies
|
French | 222.7 KB | ||
| 2023-11-16 18:30 |
Levée de fonds de 0,5 million d'euros
|
French | 237.9 KB |
Automate Your Workflow. Get a real-time feed of all Neovacs filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Neovacs
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Neovacs via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
